WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) today announced results of the LUNAR (Limiting UNdertreatment of Lipids in Acute Coronary Syndrome with Rosuvastatin) study, which showed ...

New Savings Card Allows Eligible Patients to Get CRESTOR for Just $8 More Than the Average Copay of a Generic Statin * For commercially insured patients, the CRESTOR Savings Card offers savings on out ...

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Citron Pharma LLC, a rapidly growing, US based, generic pharmaceutical company confirmed that on Tuesday, July 19, its licensing partner received final approval ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the first generic rosuvastatin calcium tablets for the treatment of high triglycerides and ...

"The law does not require that no competent attorney or alert inventor could have avoided the error sought to be corrected by reissue." On December 14, 2012, in In re ...

Late last year, in AstraZeneca v. Aurobindo (In re Rosuvastatin Calcium Patent Litigation), the Federal Circuit affirmed that a reissue patent covering the active ingredient of Crestor® was valid, ...

The U.S. Food and Drug Administration today approved the first generic version of Crestor (rosuvastatin calcium) tablets for the following uses: in combination with diet for the treatment of high ...

In February, the U.S. Food and Drug Administration approved new criteria for the prescribing of the cholesterol-lowering drug (statin) Crestor (rosuvastatin calcium) to include people at low risk for ...

Chicago, IL, (April 2, 2003) – New Phase III data presented today at the American College of Cardiology (ACC) 52nd Annual Scientific Session show that AstraZeneca’s investigational lipid-lowering ...

New Savings Card Allows Eligible Patients to Get CRESTOR for Just $8 More Than the Average Copay of a Generic Statin* WILMINGTON, Del., Nov 07, 2011 (BUSINESS WIRE) -- AstraZeneca today announced the ...